- Home
- PCRX
as of 02-18-2026 3:53pm EST
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
| Founded: | 2006 | Country: | N/A |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.0B | IPO Year: | N/A |
| Target Price: | $35.33 | AVG Volume (30 days): | 775.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $18.80 - $27.64 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 6.21% | Revenue Growth (next year): | 8.26% |
| P/E Ratio: | 48.25 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | -35.82% |
AI-Powered PCRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Pacira BioSciences Inc. (PCRX)
Chief Administrative Officer
Avg Cost/Share
$20.53
Shares
13,137
Total Value
$269,702.61
Owned After
131,303
SEC Form 4
Senior Vice President, Finance
Avg Cost/Share
$20.81
Shares
4,000
Total Value
$83,240.00
Owned After
52,313.242
SEC Form 4
Senior Vice President, Finance
Avg Cost/Share
$24.24
Shares
1,416
Total Value
$34,323.84
Owned After
52,313.242
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$25.14
Shares
9,104
Total Value
$228,874.56
Owned After
56,250
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$25.03
Shares
15,896
Total Value
$397,876.88
Owned After
56,250
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| WILLIAMS KRISTEN | PCRX | Chief Administrative Officer | Feb 2, 2026 | Sell | $20.53 | 13,137 | $269,702.61 | 131,303 | |
| RIKER LAUREN | PCRX | Senior Vice President, Finance | Feb 2, 2026 | Sell | $20.81 | 4,000 | $83,240.00 | 52,313.242 | |
| RIKER LAUREN | PCRX | Senior Vice President, Finance | Jan 5, 2026 | Sell | $24.24 | 1,416 | $34,323.84 | 52,313.242 | |
| Cross Shawn | PCRX | Chief Financial Officer | Dec 10, 2025 | Sell | $25.14 | 9,104 | $228,874.56 | 56,250 | |
| Cross Shawn | PCRX | Chief Financial Officer | Dec 9, 2025 | Sell | $25.03 | 15,896 | $397,876.88 | 56,250 |
Compare PCRX vs Leading Stocks
See how PCRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PCRX Pacira BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.